The efficacy of ciprofloxacin in preventing infection among patients with chemotherapy induced neutropenia in a university medical center in Ira
Phase 2
Completed
- Conditions
- Condition 1: Neutropenia. Condition 2: Fever.AgranulocytosisFever, unspecified
- Registration Number
- IRCT2015092924266N1
- Lead Sponsor
- AJA University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Absolute neutrophil count < 500 or less 1000 with predicted fall to below 500 in 48-72 hours; History of Malignancy.
Exclusion criteria: Fever or Any sign of clinical or microbiological infection; Any history of antibiotic consumption lately before admission.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fever. Timepoint: After intervention. Method of measurement: Body core temperature by Thermometer.
- Secondary Outcome Measures
Name Time Method Bacterial Infection. Timepoint: After intervention. Method of measurement: Blood, urine or sputum culture.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie ciprofloxacin's efficacy in preventing infections in chemotherapy-induced neutropenia patients in IRCT2015092924266N1?
How does ciprofloxacin compare to other fluoroquinolones in preventing febrile neutropenia in Iranian oncology settings?
Are there specific biomarkers that predict response to ciprofloxacin prophylaxis in patients with chemotherapy-induced agranulocytosis?
What are the potential adverse events associated with ciprofloxacin use in neutropenic patients undergoing cancer treatment?
What combination therapies or alternative antibiotics are being explored alongside ciprofloxacin for managing infection risk in chemotherapy-induced neutropenia?